LEADER Program Results for 2009: an Activity and Spectrum Analysis of Linezolid Using 6,414 Clinical Isolates from 56 Medical Centers in the United States
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
The LEADER Program monitors the in vitro activity of linezolid in sampled U.S. medical centers using reference broth microdilution methods with supporting molecular investigations in a central laboratory design. This report summarizes data obtained in 2009, the 6th consecutive year of this longitudinal study. A total of 6,414 isolates from 56 medical centers in all nine Census regions across the United States participated in 2009. For the six leading species/groups, the following linezolid MIC 90 values were observed: Staphylococcus aureus , 2 μg/ml; coagulase-negative staphylococci (CoNS), 1 μg/ml; Enterococcus spp., 2 μg/ml; Streptococcus pneumoniae , 1 μg/ml; viridans group streptococci, 1 μg/ml; and beta-hemolytic streptococci, 1 μg/ml. Linezolid resistance was only 0.34% overall, with no evidence of significant increase in the LEADER Program since 2006. The predominant linezolid resistant mechanism found was a G2576T mutation in the 23S rRNA. L3/L4 riboprotein mutations were also found. The mobile multidrug-resistant cfr gene was found in four strains (two S. aureus strains and one strain each of S. epidermidis and S. capitis ) from four different states, suggesting persistence but a lack of dissemination. Linezolid continues to exhibit excellent activity and spectrum, and this study documents the need for continued monitoring of emerging mechanisms of resistance over a wide geographic area.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toh, S., Xiong, L., Arias, C. A., Villegas, M. V., Lolans, K., Quinn, J., & Mankin, A. S. (2007) · Molecular Microbiology · doi:10.1111/j.1365-2958.2007.05744.x · Cited by 338 · cited 1×
“streptogramin A (phLOPSA) agents has been described previously (21) and has subsequently been identified in numerous human cases of staphylococcal infection (1, 22, 28).”
BackgroundResponse to Emerging Infection Leading to Outbreak of Linezolid-Resistant Enterococci
Kainer, M. A., Devasia, R. A., Jones, T. F., Simmons, B. P., Melton, K., Chow, S., Broyles, J., Moore, K. L., Craig, A. S., & Schaffner, W. (2007) · Emerging Infectious Diseases · doi:10.3201/eid1307.070019 · Cited by 96 · cited 1×
“0%) among surveyed isolates (11, 16), individual cases have been widely reported and have been associated either with prolonged drug exposure in at-risk patient populations or with breaks in infection control practices leading to local outbreak or endemic occurrences (10, 12, 19, 20, 24, 29, 31).”
Background
Cited by
Intrinsic and acquired resistance mechanisms in enterococcus
Hollenbeck, B. L., & Rice, L. B. (2012) · Virulence · doi:10.4161/viru.21282 · Cited by 795
Resistance to Linezolid Caused by Modifications at Its Binding Site on the Ribosome
Long, K. S., & Vester, B. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05702-11 · Cited by 375
The emerging problem of linezolid-resistant Staphylococcus
Gu, B., Kelesidis, T., Tsiodras, S., Hindler, J., & Humphries, R. M. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks354 · Cited by 332
The oxazolidinones: past, present, and future
Shaw, K. J., & Barbachyn, M. R. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06330.x · Cited by 259
Mendes, R. E., Deshpande, L. M., & Jones, R. N. (2014) · Drug Resistance Updates · doi:10.1016/j.drup.2014.04.002 · Cited by 221
Self-citationThe Order Bacillales Hosts Functional Homologs of the Worrisome cfr Antibiotic Resistance Gene
Hansen, L. H., Planellas, M. H., Long, K. S., & Vester, B. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00673-12 · Cited by 53
Metadata
- Authors
- Farrell, D. J., Mendes, R. E., Ross, J. E., Sader, H. S., & Jones, R. N.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2011-08
- Volume
- 55
- Issue
- 8
- Pages
- 3684-3690
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2169882349
- Cited by
- 89
- References
- 2
- FWCI
- 7.10
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.